PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.93%
Negative revenue growth while Healthcare median is -0.44%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-34.20%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
61.81%
EBIT growth exceeding 1.5x Healthcare median of 4.48%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
61.81%
Operating income growth exceeding 1.5x Healthcare median of 3.79%. Joel Greenblatt would see if unique processes drive exceptional profitability.
53.38%
Net income growth exceeding 1.5x Healthcare median of 5.03%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
55.11%
EPS growth exceeding 1.5x Healthcare median of 9.09%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
55.11%
Diluted EPS growth exceeding 1.5x Healthcare median of 9.01%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
5.26%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.26%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-136.34%
Negative OCF growth while Healthcare median is -17.43%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-164.10%
Negative FCF growth while Healthcare median is -14.16%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
373.08%
5Y CAGR of 373.08% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
-43.99%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-41900.71%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
60.67%
OCF/share CAGR of 60.67% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
89.54%
3Y OCF/share growth of 89.54% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-3781.62%
Negative 10Y net income/share CAGR vs. Healthcare median of 30.04%. Seth Klarman might see a fundamental problem if peers maintain growth.
-193.75%
Negative 5Y CAGR while Healthcare median is 21.37%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-402.19%
Negative 3Y CAGR while Healthcare median is 12.64%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5906.98%
Equity/share CAGR exceeding 1.5x Healthcare median of 11.12% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-16.70%
Negative 5Y equity/share growth while Healthcare median is 4.42%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-14.43%
Negative 3Y equity/share growth while Healthcare median is -1.32%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.81%
AR shrinking while Healthcare median grows. Seth Klarman sees potential advantage unless it signals declining demand.
15.72%
Inventory growth of 15.72% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.21%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-2.95%
Negative BV/share change while Healthcare median is -3.04%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.65%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-56.11%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-13.48%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.